PPT-Switch to LPV/ r + 3TC OLE

Study LPV r bid 3TC or FTC qd NRTI N 127 N 123 LPV r bid 3TCFTC qd Design Randomisation 1 1 Openlabel Objective Primary Endpoint proportion without treatment failure at W48 . (with perspectives from well-resourced and resource-limited settings). Gareth Tudor-Williams. Imperial College London. UK. Where would you prefer to be right now?. Langkawi resort?. Attending a workshop?. STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . Susan M. Graham . Assistant Professor, Medicine and Global Health. Adjunct Assistant Professor, Epidemiology. Presentation prepared by: . Susan M. Graham. Last Updated: . October 29, 2014. Susan M. Graham, MD MPH PhD. vs. PI/r . monotherapy. Study PIVOT. Study MOBIDIP. LPV/r monotherapy (N = 82). Design. Randomisation. 1: 1. Open-label. Objective. Primary endpoint. : failure rate at W96 by ITT, defined as 1) a confirmed HIV . Martina Penazzato MD, PhD. Paediatric lead, HIV Department. World Health Organization, Geneva. Background. 1.8 million children were estimated to live with HIV in 2017. In 2017, only 51 % of HIV-exposed infants received EID (by 2mo). M. edications. in . Paediatrics. Dr Leon J. Levin. Head - . Paediatric. HIV . Programmes. Right to Care. New Regimens for DOH and Private Sector in SA.  . 0-3 years. >3years and >10 kg.  . 1. Dr. S . Ntshalintshali. Ngwelezana. hospital. November 2016. HIV prevalence in RSA. The national estimate for HIV prevalence among South Africans in 2012 was 12.2. % (. 95% CI: 11.4–13.1). This estimate is statistically significantly different (p<0.001), from the 2008 national estimate of 10.6% (95% CI: 9.8–11.6). . Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent –. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RESULTS FROM THE GEMINI STUDIES. 1. Fundación Huesped, Buenos Aires, Argentina; . 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . ARV . strategies. DOR > DRV/r 1st line. (DRIVE-FORWARD W96). DTG. monotherapy. Switch PI/r-DTG (NEAT22). Switch RPV+DTG . (SWORD). Test and . Treat. D/C/F/TAF . (DIAMOND). −10% noninferiority margin for individual studies.. Dr Laura Oyiengo. NATIONAL AIDS STI CONTROL PROGRAM. MOH. BACKGROUND. As a country with the fourth largest Pediatric HIV epidemic in the world, Pediatricians need to be involved in programming, decision making and management of children and adolescent living with HIV and also in PMTCT programming.. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. Bob Harrington, MD. University of Washington . Presentation prepared by: . Presenter. Last Updated: . Date. Early Vs Deferred HAART . Strategic Timing of . AntiRetroviral. Treatment (START) Study. START: 2015. DRIVE SHIFT. Switch to Doravirine-TDF-3TC versus Continued Baseline Regimen. DRIVE SHIFT: Design. Source: Johnson M, et al. J . Acquir. . Immun. . Defic. . Syndr. . 2019;81:463-72.. Design: . Open-label, non-inferiority trial in adults with suppressed HIV RNA while taking 2 NRTIs plus anchor drug, randomized (2:1) to immediately switch to fixed-dose .